<DOC>
	<DOCNO>NCT02607657</DOCNO>
	<brief_summary>This Phase I , open-label , randomize , parallel trial evaluate pharmacokinetics Eplerenone tablet different dosage ( 25 mg daily , 50 mg daily , 100 mg ( 2 tablet 50 mg ) daily 50 mg twice daily ) . Sample size 96 participant ( 24 per treatment group ) , male female , age 18 50 years-old . Primary objective evaluate pharmacokinetics Eplerenone tablet different dosage , secondary objective evaluate safety tolerability investigational product . Study overall duration approximately 12 week , include enrollment follow-up visit . Participants admit period 36 hour , investigational product administer , blood sample , pre-determined time period , collect pharmacokinetics . Primary endpoint obtain pharmacokinetics parameter . Additionally , safety assess adverse event occurrence laboratory exams evaluation .</brief_summary>
	<brief_title>Pharmacokinetics Eplerenone Tablet</brief_title>
	<detailed_description />
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<criteria>Male female study participant , age 18 50 yearsold ; Healthiness , accord clinical , laboratory electrocardiographic evaluation ; Ability understand nature objective trial , include risk adverse event ; willingness cooperate researcher proceed accord study requirement , shall confirm Informed Consent Form signature . Known hypersensitivity investigational product ( Eplerenone ) chemically related compound ; history serious adverse reaction hypersensitivity drug ; History presence hepatic gastrointestinal disease , condition interferes drug absorption , distribution , excretion metabolism ; Chronic therapy drug , except oral contraceptive ; History hepatic , kidney , lung , gastrointestinal , epileptic , hematologic psychiatric disease ; hypotension hypertension , etiology , require pharmacological treatment ; history myocardial infarction , angina and/or heart failure ; Electrocardiographic finding , investigator criterion , recommend study participation ; Deviations screen laboratory result consider clinically relevant researcher , prevent subject participate trial ; Smoking ; Intake 5 cup coffee tea per day ; Unusual food habit , e.g. , vegetarian ; History drug alcohol addiction excessive alcohol consumption ( &gt; 35 g/day ) ; Use regular medication within 2 week prior study enrollment use medication within one week prior study enrollment , except oral contraceptive case , base drug 's metabolite 's halflife , complete elimination assume ; Hospitalization reason 8 week trial ; Treatment , within 6 month trial , drug know wellestablished toxic potential major organ ; Participation experimental research administration experimental drug within 3 month trial ; Donation loss 450 mL blood within 3 month trial 3 donation ( woman ) /4 donation ( men ) blood within 12 month trial ; Any condition , accord investigator 's best judgement , prevents subject participate trial ; Pregnancy , labor miscarriage 12 week admission predict date .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>